A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Phase 1
Completed
- Conditions
- Ovarian CancerEndometrial CancerSoft Tissue SarcomaTriple Negative Breast CancerPancreas CancerSolid TumorsColorectal CancerNeoplasmsBreast CancerColon Cancer
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Esperas Pharma Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT02632448
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธKarmanos Cancer Institute, Detroit, Michigan, United States
๐จ๐ฆTom Baker Cancer Centre, Calgary, Alberta, Canada
ยฉ Copyright 2025. All Rights Reserved by MedPath